Triple A.....all the players are active in MS (Biogen, Anavex and Wayne State/Dr Lisak). If Aducanumab is turned down or delayed by the FDA, Biogen and Vounatsos will have to move to bolsterer the MS business. If not successful, Vounatsos will be looking for a new job.
From a previous post:
Tred.....this discussion of the 2-73 and the MS MTA with Biogen has gone around the track a number of times. The consensus on why an agreement for Anavex and Biogen to partner on development did not materialize comes down to Alzheimer's and both companies having primary drugs candidates for the disease. Biogen would not develop 2-73 for MS without control over it for Alzheimer's after spending maybe $10M developing Aducanumab. CM wisely saw that losing control of 2-73 would allow Biogen to bury it in order to protect its current MS drug line ( bringing in 70% of BIIB's revenue ) and Aducanumab. Biogen also has a not so promising remyelination drug in clinical trials. So obviously no deal.
Dr.Lisak's preclinical work on 2-73's over the last tree years has more than shown 2-73's potential as remyelination drug for MS. IMHO, a MS P1/2 trial will come before year end and Dr Lisak, a world recognized leader in MS treatment/research, will play major part if not lead it. WSU is one of the US's leading MS centers and currently treats over 3000 MS patients....what better location to conduct a clinical trial with possible considerable research $'s.
Market Data 
Markets 
AI
